Vermillion targets $31.5M from funding round

05/10/2013 | GenomeWeb Daily News (free registration)

Austin, Texas-based molecular diagnostics firm Vermillion hopes to raise as much as $31.5 million through the sale of 8 million shares of stock. Part of the proceeds will go toward improving sales and reimbursements for the company's OVA1 assay, which is used to distinguish malignant from benign ovarian tumors.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI